Tyvaso® (treprostinil) – New indication
April 1, 2021 - United Therapeutics announced the FDA approval of Tyvaso (treprostinil), for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
Download PDF
